We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sanofi's Next-Generation Rabies Vaccine Secures Approval in EU
Read MoreHide Full Article
Key Takeaways
Sanofi gains EC approval for VaxRabeo, its next-generation rabies vaccine for individuals of all ages.
VaxRabeo offers improved temperature stability, an extended shelf life & a lower risk of allergic reactions.
Clinical studies show comparable immune responses, while Sanofi plans a U.S. regulatory filing in Q4 2026.
Sanofi (SNY - Free Report) announced that the European Commission (EC) has approved its next-generation rabies vaccine, VaxRabeo, for individuals of all ages. This marks the vaccine’s first marketing authorization and allows its use for both pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP).
The approval was largely anticipated following a positive opinion issued by the European Medicines Agency’s Committee for Medicinal Products for Human Use in September 2026, which recommended the vaccine’s authorization.
The vaccine utilizes the same viral strain as Sanofi’s existing rabies vaccines, Verorab and Imovax Rabies. The next-generation vaccine is designed to lower the risk of allergic reactions while offering an extended shelf life and improved temperature stability compared with the company's existing rabies vaccines.
The newly approved vaccine provides flexible immunization schedules, including a two-dose regimen for PrEP and a four-dose regimen for PEP in previously unvaccinated individuals.
Rabies is a viral disease transmitted mainly through the saliva of infected animals, particularly dogs. Although rabies is preventable through timely vaccination, it is almost invariably fatal once clinical symptoms develop. Children are particularly vulnerable, with individuals below 15 years of age accounting for approximately 40% of people bitten by potentially rabid animals.
Year to date, SNY’s shares have risen 1.2% compared with the industry’s 26.7% growth.
Image Source: Zacks Investment Research
SNY’s Clinical Studies Support VaxRabeo's EU Approval
The EC's decision was backed by clinical studies evaluating VaxRabeo against Sanofi’s existing rabies vaccines in both PrEP and PEP settings across different age groups.
VaxRabeo demonstrated comparable protective antibody levels in pre-exposure vaccination and a similar immune response in post-exposure vaccination. It also showed a strong booster response when administered 12 or 24-36 months after the initial PrEP.
The vaccine's safety profile was consistent with that of existing rabies vaccines, with no major safety concerns reported.
Sanofi already has an established presence in the rabies vaccine market through its marketed products, Verorab and Imovax Rabies. The approval of VaxRabeo strengthens Sanofi's rabies vaccine portfolio and expands its preventive vaccine offerings in Europe. Beyond Europe, Sanofi is pursuing regulatory authorization for SP0087/VaxRabeo in the United States. The company expects to submit a regulatory application for the vaccine in the fourth quarter of 2026.
Over the past 30 days, earnings per share estimates for Amneal Pharmaceuticals have increased from $1.03 to $1.06 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $1.16 to $1.21. AMRX’s shares have jumped 73.7% year to date.
Amneal Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 27.21%.
Over the past 30 days, loss per share estimates for AC Immune have narrowed from 60 cents to 54 cents for 2026. Over the same period, estimates for 2027 earnings per share have increased from 17 cents to 43 cents. ACIU’s shares have declined 33.1% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with an average surprise of 37.79%.
Over the past 30 days, loss per share estimates for Adaptive Biotechnologies have narrowed from 55 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have also improved from 17 cents to 3 cents. ADPT’s shares have surged 75.2% year to date.
Adaptive Biotechnologies’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 53.62%.
Image: Bigstock
Sanofi's Next-Generation Rabies Vaccine Secures Approval in EU
Key Takeaways
Sanofi (SNY - Free Report) announced that the European Commission (EC) has approved its next-generation rabies vaccine, VaxRabeo, for individuals of all ages. This marks the vaccine’s first marketing authorization and allows its use for both pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP).
The approval was largely anticipated following a positive opinion issued by the European Medicines Agency’s Committee for Medicinal Products for Human Use in September 2026, which recommended the vaccine’s authorization.
The vaccine utilizes the same viral strain as Sanofi’s existing rabies vaccines, Verorab and Imovax Rabies. The next-generation vaccine is designed to lower the risk of allergic reactions while offering an extended shelf life and improved temperature stability compared with the company's existing rabies vaccines.
The newly approved vaccine provides flexible immunization schedules, including a two-dose regimen for PrEP and a four-dose regimen for PEP in previously unvaccinated individuals.
Rabies is a viral disease transmitted mainly through the saliva of infected animals, particularly dogs. Although rabies is preventable through timely vaccination, it is almost invariably fatal once clinical symptoms develop. Children are particularly vulnerable, with individuals below 15 years of age accounting for approximately 40% of people bitten by potentially rabid animals.
Year to date, SNY’s shares have risen 1.2% compared with the industry’s 26.7% growth.
Image Source: Zacks Investment Research
SNY’s Clinical Studies Support VaxRabeo's EU Approval
The EC's decision was backed by clinical studies evaluating VaxRabeo against Sanofi’s existing rabies vaccines in both PrEP and PEP settings across different age groups.
VaxRabeo demonstrated comparable protective antibody levels in pre-exposure vaccination and a similar immune response in post-exposure vaccination. It also showed a strong booster response when administered 12 or 24-36 months after the initial PrEP.
The vaccine's safety profile was consistent with that of existing rabies vaccines, with no major safety concerns reported.
Sanofi already has an established presence in the rabies vaccine market through its marketed products, Verorab and Imovax Rabies. The approval of VaxRabeo strengthens Sanofi's rabies vaccine portfolio and expands its preventive vaccine offerings in Europe. Beyond Europe, Sanofi is pursuing regulatory authorization for SP0087/VaxRabeo in the United States. The company expects to submit a regulatory application for the vaccine in the fourth quarter of 2026.
SNY’s Zacks Rank & Stocks to Consider
Sanofi currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Amneal Pharmaceuticals (AMRX - Free Report) , AC Immune (ACIU - Free Report) and Adaptive Biotechnologies (ADPT - Free Report) , carrying a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Over the past 30 days, earnings per share estimates for Amneal Pharmaceuticals have increased from $1.03 to $1.06 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $1.16 to $1.21. AMRX’s shares have jumped 73.7% year to date.
Amneal Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 27.21%.
Over the past 30 days, loss per share estimates for AC Immune have narrowed from 60 cents to 54 cents for 2026. Over the same period, estimates for 2027 earnings per share have increased from 17 cents to 43 cents. ACIU’s shares have declined 33.1% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with an average surprise of 37.79%.
Over the past 30 days, loss per share estimates for Adaptive Biotechnologies have narrowed from 55 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have also improved from 17 cents to 3 cents. ADPT’s shares have surged 75.2% year to date.
Adaptive Biotechnologies’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 53.62%.